The luminal A, B, and HER2+ breast cancer subtypes use estrogen/progesterone and HER2 receptor overexpression and activation, respectively, to drive tumor growth while the TNBC subtype lacks comparable overexpression of these receptors (Table 1). This evidence concerns the gene ERBB2 and neoplasm.